Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients?
Neuromuscular blocking drugs may be administered over several days to patients in the intensive care unit (ICU), but their pharmacokinetics have been studied at only one point in time, or assumed to be constant throughout the period of administration. We sought to determine if, in individual patients, the pharmacokinetics of vecuronium changed over the course of its administration in the ICU. In six critically ill patients, we measured plasma vecuronium concentrations during two periods: first, during initial administration of vecuronium and second, after its administration continuously for 3-6 days. A pharmacokinetic model was fitted to these plasma concentration data, and its parameters permitted to vary between the periods to determine if they had altered. Individual clearance values during the study ranged from 1.4 to 4.4 ml kg-1 min-1. During prolonged administration, vecuronium clearance increased in three and decreased in two patients. This change ranged from a 61% decrease to a 58% increase, and was not linked to any clinical factor. The steady-state volume of distribution (range 368-1765 ml kg-1; median 494 ml kg-1) did not change in any patient during the study. The change in clearance of vecuronium during its prolonged administration in critically ill patients suggests that future studies of neuromuscular blocking drugs in the ICU should take account of their changing pharmacokinetics over the course of administration.
Department of Anesthesia, University of California, San Francisco 94143-0648, USA.
V
V
Segredo
J E
JE
Caldwell
P M
PM
Wright
M L
ML
Sharma
L D
LD
Gruenke
R D
RD
Miller
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003422:Critical Care; D016638:Critical Illness / Q000628:therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008956:Models, Chemical; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage / Q000097:blood*; D012121:Respiration, Artificial; D014673:Vecuronium Bromide / Q000008:administration & dosage / Q000097:blood*
D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide